Home > Resources > Company Profiles > Neuralstem, Incorporated

Neuralstem, Incorporated (CUR)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
I. Richard Garr, JD , Founder/CEO/President/Director/General Counsel
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

I. Richard Garr, JD, Founder/CEO/President/Director/General Counsel

9700 Great Seneca Highway

Rockville, MD 20850

US Map it

Phone: (301) 366-4841

Fax:

www.neuralstem.com



Overview

A biotechnology company focused on developing and commercializing human neural stem cell technology in the emerging field of regenerative medicine.

Employees

Number of Employees: 2
Revenue per Employee: $181,267

Top Executives

Dr. Karl Johe, Ph.D, Founder/Chairman of the Board/Chief Scientific Officer/Director
John Conron, CPA, CFO

Board of Directors

Dr.Malcolm R. Currie, Director
Scott V. Ogilvie, Director
Dr. Karl Johe, Ph.D, Founder/Chairman of the Board/Chief Scientific Officer/Director

William C. Oldaker, Director

Financials

Quarterly
Annual

Income Statement 09/2008 06/2008 03/2008 12/2007
Sales 1 -1 1 0
Gross Operating Profit -1 1 -1 45.73 K.
Operating Income before D & A (EBITDA) -2.95 Mil. -2.28 Mil. -2.08 Mil. -1.46 Mil.
Total Income Before Interest Expenses (EBIT) -2.96 Mil. -2.27 Mil. -2 Mil. -1.42 Mil.
Total Net Income -2.96 Mil. -2.27 Mil. -2.01 Mil. -1.42 Mil.
Basic EPS, Total -0.09 -0.07 -0.09 -0.05
Diluted EPS, Total -0.09 -0.07 -0.09 -0.05

BALANCE STATEMENT 09/2008 06/2008 03/2008 12/2007
Cash and Equivalents 6.97 Mil. 8.26 Mil. 7.4 Mil. 5.35 Mil.
Total Assets 7.05 Mil. 8.38 Mil. 7.53 Mil. 5.48 Mil.
Total Liabilities 936.11 K. 494.01 K. 1.02 Mil. 865.59 K.
Total Capitalization 6.46 Mil. 8.2 Mil. 6.81 Mil. 4.77 Mil.

Cash Flow 09/2008 06/2008 03/2008 12/2007
Net Cash From Continuing Operations -3.08 Mil. -1.69 Mil. -4 Mil. -2.88 Mil.
Net Cash From Investing Activities -83.68 K. -31.63 K. -229.63 K. -108.07 K.
Net Cash From Financing Activities 2.72 Mil. 2.57 Mil. 9.83 Mil. 6.52 Mil.
Net Change in Cash & Cash Equivalents -437.15 K. 854.11 K. 5.6 Mil. 3.54 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006
Sales 1 0 0
Gross Operating Profit 306.06 K. 265.76 K. 309.14 K.
Operating Income before D & A (EBITDA) -6.34 Mil. -3.11 Mil. -1.52 Mil.
Total Income Before Interest Expenses (EBIT) -6.17 Mil. -3.14 Mil. -1.55 Mil.
Total Net Income -6.17 Mil. -3.15 Mil. -1.65 Mil.
Basic EPS, Total -0.24 -0.13 -0.16
Diluted EPS, Total -0.24 -0.13 -0.16

BALANCE STATEMENT 2008 2007 2006
Cash and Equivalents 7.4 Mil. 1.81 Mil. 526.38 K.
Total Assets 7.53 Mil. 1.85 Mil. 526.38 K.
Total Liabilities 1.02 Mil. 359.78 K. 1 Mil.
Total Capitalization 6.81 Mil. 1.57 Mil. -431.78 K.

Cash Flow 2008 2007 2006
Net Cash From Continuing Operations -4 Mil. -3.33 Mil. -728.59 K.
Net Cash From Investing Activities -229.63 K. -59.21 K. -18.34 K.
Net Cash From Financing Activities 9.83 Mil. 4.67 Mil. 1.23 Mil.
Net Change in Cash & Cash Equivalents 5.6 Mil. 1.28 Mil. 487.33 K.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Athersys, Incorporated
90.85 Mil.
StemCells, Incorporated
90.36 Mil.
Curis Incorporated
90.33 Mil.
Biosante Pharmaceuticals, Incorporated
94.32 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented